Welcome to our dedicated page for Propanc Bio news (Ticker: PPCB), a resource for investors and traders seeking the latest updates and insights on Propanc Bio stock.
Propanc Biopharma, Inc. develops proenzyme-based therapeutics for chronic diseases, including recurrent and metastatic cancer. Its lead asset, PRP, is an intravenous formulation of trypsinogen and chymotrypsinogen designed to target cancer stem cells, epithelial-mesenchymal transition, tumor angiogenesis, migration, and cancer cell death in solid tumors such as pancreatic and ovarian cancer.
Company news commonly covers PRP preclinical data, clinical-development preparations, pharmacokinetic assay work, GMP and trial-enabling activities, intellectual-property filings for proenzyme formulations and production methods, and research collaborations with the Universities of Jaén and Granada. Updates also include corporate financing, preferred-stock transactions, and periodic financial results.
Propanc Biopharma (Nasdaq: PPCB) outlined how its lead candidate PRP, a fixed‑ratio combination of pancreatic proenzymes trypsinogen and chymotrypsinogen, may address aggressive, RAS‑driven solid tumors such as pancreatic ductal adenocarcinoma (PDAC) by promoting differentiation, reversing epithelial‑mesenchymal transition (EMT), and targeting cancer stem cells.
Administered once weekly by IV, PRP showed >90% mean tumor growth inhibition, marked metastasis reduction, and >2.5‑fold median survival extension in advanced PDAC preclinical models, and holds FDA Orphan Drug Designation for pancreatic cancer. Propanc plans a Phase 1b first‑in‑human study in 40–45 advanced solid‑tumor patients, with GMP manufacturing and clinical partnerships advancing in 2026. The company contrasts PRP’s non‑cytotoxic, phenotype‑reprogramming approach with pathway‑centric RAS inhibitors from Revolution Medicines and Erasca, positioning PRP as potentially complementary for long‑term, low‑toxicity treatment.
Propanc Biopharma (Nasdaq: PPCB) reported new preclinical and early translational results for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC). In orthotopic and patient-derived xenograft models of advanced PDAC, 3x-weekly intravenous PRP achieved >90% mean tumor growth inhibition versus vehicle controls, marked metastatic burden reductions in liver and peritoneum, and a median overall survival extension of more than 2.5-fold in treated animals.
According to Propanc, PRP also remodeled the tumor microenvironment and enhanced sensitivity of chemo‑resistant PDAC cells to gemcitabine/nab‑paclitaxel. The company plans to accelerate a Phase 1b first‑in‑human study in approximately 30–40 advanced solid‑tumor patients, targeting clinical trial application submission in Australia in the coming months. PRP has FDA Orphan Drug Designation for pancreatic cancer, with GMP manufacturing targeted for late 2026 and a memorandum of understanding with Avance Clinical to support trial execution.
Propanc Biopharma (Nasdaq: PPCB) announced completion of the first $500,000 tranche of its previously approved $5.0 million share repurchase program, executed within the first 30 days of commencement. The company said it intends to continue buybacks under Rule 10b5-1, using methods such as open market and privately negotiated transactions, with no obligation to repurchase a specific number of shares.
Management stated it views Propanc as significantly undervalued as it advances a planned world-first Phase 1b, first-in-human study of its lead candidate PRP in approximately 40–45 advanced solid tumor patients in Australia. The repurchase program may be modified, discontinued, or suspended at any time.
Propanc Biopharma (Nasdaq: PPCB) announced publication of joint research with the Universities of Jaén and Granada in peer‑reviewed journal Microbial Cell Factories, evaluating recombinant trypsinogen and chymotrypsinogen for biotechnology applications, including potential human therapeutic use against chronic diseases such as cancer and fibrosis.
According to Propanc, the work supports scalable production of stable, purified recombinant proenzymes forming a backup candidate, rec‑PRP, to its bovine‑derived lead asset PRP, which is targeting a Phase 1b first‑in‑human study in advanced solid tumor patients in early 2027. Rec‑PRP is planned for small‑scale, non‑GMP production to compare with PRP and define a clinical regulatory pathway, and may offer long shelf life without refrigeration, aiding global distribution.
Propanc Biopharma (Nasdaq:PPCB) signed a non-binding Memorandum of Understanding with Avance Clinical to support a planned Phase 1b, first-in-human trial of PRP, its lead candidate for advanced solid tumors.
The collaboration focuses on early-phase trial design, patient safety, and building data to progress PRP toward proof-of-concept studies.
Propanc Biopharma (Nasdaq:PPCB) announced a $5.0 million share repurchase program, beginning with a first tranche of up to $500,000 over the next 30 days. Purchases may occur under Rule 10b5-1 through various methods and can be adjusted, suspended, or discontinued at any time.
Propanc Biopharma (Nasdaq:PPCB) outlined its 2026 manufacturing plan for PRP, supporting a planned Phase 1b, first-in-human study in 30–40 advanced solid tumor patients.
The CEO toured a European GMP CDMO as the team targets preproduction in August 2026, an engineering run in October 2026, and GMP manufacture from December 2026 to back a 2026 Australian trial application.
Propanc Biopharma (Nasdaq:PPCB) authorized a $5.0 million share repurchase program for its common stock. According to Propanc, buybacks will be considered when the market price understates intrinsic value and relative to other capital uses.
The company is progressing its lead asset, PRP, toward a pivotal Phase 1b First-In-Human study in 30–40 advanced cancer patients and holds US FDA Orphan Drug Designation for pancreatic cancer, which provides seven-year market exclusivity post approval. The program may be executed via various methods and can be modified or suspended at any time.
Propanc Biopharma (Nasdaq:PPCB) announced that CEO James Nathanielsz attended the keynote “Rejuvenation and Health: Science for an Ageing Society” at the University of Granada’s Hospital Real in Spain.
According to Propanc, the company is collaborating with the Universities of Granada and Jaén and plans a Phase 1b First-In-Human study of lead asset PRP in advanced cancer patients.
Propanc Biopharma (Nasdaq:PPCB) highlighted emerging pancreatic cancer advances and outlined development plans for its lead asset, PRP. PRP has USFDA Orphan Drug Designation for pancreatic cancer and showed encouraging compassionate use data in terminal patients.
Propanc plans a Phase 1b first‑in‑human CTA in Australia in 2026 for 30–40 advanced solid tumor patients using weekly IV PRP at higher doses, followed by two Phase 2, 60‑patient studies in pancreatic and ovarian cancers to establish proof of concept.